Saturday, April 18th. Here's what matters right now. Big tech is racing into drug discovery with dedicated AI platforms from both OpenAI and Amazon this week. Bitcoin spiked to 78,000 dollars on news that Iran would reopen the Strait of Hormuz, then slipped back to 76,500 as Tehran reversed course hours later. US mining costs just jumped 47% on fresh tariffs, and the digital asset treasury trade is facing its first real stress test with 14 and a half billion dollars in unrealized losses across the sector. Let's get into it.
Something significant is happening at the intersection of AI and biology, and this week it got very real very fast. OpenAI announced GPT-Rosalind, a biology-focused model built to accelerate biotech and pharma research and development. This isn't a chatbot answering medical questions. Rosalind is designed to synthesize evidence, generate hypotheses, plan experiments, and execute multi-step research tasks. Researchers can query databases, read current papers, access over 50 scientific tools through a free Life Sciences plugin for Codex, and get suggested next experiments. OpenAI has already lined up partnerships with Amgen, Moderna, and Thermo Fisher Scientific. This came just days after GPT-5.4-Cyber for cybersecurity, signaling OpenAI is aggressively verticaling its model lineup into specific industries.
Meanwhile, Amazon Web Services launched Amazon Bio Discovery, an AI platform that lets scientists run complex computational drug discovery workflows without writing a single line of code. The platform provides access to a library of biological foundation models that generate and evaluate potential drug molecules, plus an AI agent that helps select the right models, set parameters, and interpret results. Promising candidates get forwarded to integrated lab partners for synthesis and testing, and results feed back into the system for the next design cycle. The real proof point here is a collaboration with Memorial Sloan Kettering Cancer Center, where the system generated roughly 300,000 novel antibody molecules, narrowed them to about 100,000 candidates for lab testing, and compressed what would normally take months into weeks. 19 of the top 20 global pharma companies already use AWS cloud services, so the distribution channel is already there.
And on the clinical side, Evaxion Biotech reported phase 2 data for its personalized cancer vaccine showing 86% of AI-predicted vaccine targets successfully triggered tumor-specific immune responses. The AI-Immunology platform identified these targets, and there's a positive correlation between the AI's prediction scores and the actual magnitude of immune response. The trial shows a 75% overall objective response rate in advanced melanoma patients. Three-year data is expected later this year.
Lantern Pharma also launched withZeta.ai, which they're calling the world's first multi-agent AI co-scientist for rare cancer drug discovery. It's now commercially live with subscription tiers. The pattern is unmistakable. AI in drug discovery has moved from research papers to shipping products, from demos to clinical validation, from single companies to entire platform ecosystems. The bottleneck in biology is shifting from can we find the right molecule to can we test fast enough.
Bitcoin had a wild 24 hours. The price spiked to 78,000 dollars Thursday after Iran announced it was reopening the Strait of Hormuz. Brent crude dropped nearly 13%, stocks surged, and 820 million dollars in leveraged crypto positions got liquidated, with 593 million of that coming from bearish bets alone. It was one of the biggest short liquidation events of 2026.
Then, Friday evening, Iran's parliament speaker announced the Strait would not remain open while the US blockade stayed in place. Bitcoin retraced to around 76,500. Polymarket odds of Hormuz traffic normalizing by the end of May sit at 73%, but the ceasefire deadline is just 4 days away, and if it expires without a deal, we could see another sharp reversal.
What's interesting here is the broader framing. Bitwise CIO Matt Hougan pointed out that since the Iran conflict began on February 28th, Bitcoin is up about 12% while the S&P 500 is down roughly 1% and gold has fallen about 10%. That's a 22 percentage point outperformance over gold during an active geopolitical crisis. The traditional playbook says gold goes up when bombs fall. That's not what happened. Hougan argues Bitcoin is developing a dual use case: digital gold for store of value, and an apolitical currency for a financially fragmenting world. Reports that Iran floated taxing ships in Bitcoin through the Strait reinforce the second thesis.
On the macro side, Fed Governor Christopher Waller warned that the Middle East conflict could push near-term inflation higher and complicate rate cut decisions. He expects PCE inflation around 3.5% in March against the 2% target. The Fed is widely expected to hold rates at 3.5 to 3.75% at the April 28th to 29th FOMC meeting. Treasury Secretary Bessent has signaled the Fed is open to cuts due to economic slowdown from war impacts, but Polymarket is only pricing about a 15% probability of a cut at the next decision window. So the macro setup is: elevated inflation, uncertain geopolitics, and a Fed that wants to cut but can't yet. Bitcoin is trading right in the middle of that tension.
Let's talk about what's happening underneath Bitcoin's price action, at the mining layer. The network hashrate sits at about 995 exahashes per second, just shy of the symbolic 1 zettahash milestone. Block production is healthy, averaging about 135 blocks per day against the 144 target. Foundry USA leads pool distribution at 30.3%, followed by AntPool at 19.3% and F2Pool at 11.4%.
But the economics are getting squeezed hard, especially for American miners. New Section 232 tariffs on steel, aluminum, and copper, layered on top of an existing 21.6% duty on ASIC miners imported from Southeast Asia, have pushed US Bitcoin mining deployment costs up roughly 47%. A flagship Antminer S21 XP now faces about 1,600 dollars in metal duties alone on top of the prior tariff. Mining containers and enclosures are up 10,000 to 25,000 dollars per unit.
The numbers get uncomfortable fast. Publicly listed US miners had an all-in production cost of about 74,600 dollars per Bitcoin in late March. With these tariffs, breakeven could push to somewhere between 82,000 and 85,000 dollars per coin. With Bitcoin hovering around 76,000 to 78,000, that puts a lot of domestic miners underwater on new deployments.
Large operators like Marathon, Riot, and CleanSpark with pre-tariff inventory are insulated for now. But future hardware upgrade cycles will be more expensive domestically compared to operators in tariff-free jurisdictions like Kazakhstan and Russia. The US currently anchors about 38% of global hashrate. If these cost differentials persist over 2 to 3 upgrade cycles, we could see meaningful hashrate migration away from the US, which has real implications for network security and geographic decentralization.
There's a proposed Mined in America Act that would provide subsidies and tax incentives for domestic miners, but no vote date is set. Meanwhile, miner reserves have declined by about 61,000 BTC since the start of the current cycle, with Riot, Marathon, and Core Scientific among those selling. Transaction fees remain at just 0.52% of total miner revenue, reinforcing the subsidy-heavy income model that becomes increasingly precarious after future halvings. The mining layer is under real structural pressure right now.
The digital asset treasury model, companies that hold Bitcoin on their balance sheet and raise capital to buy more, is facing its first genuine downturn. There are now over 200 publicly listed companies following some version of this strategy, and collectively they've raised about 29 to 30 billion dollars. The problem is the sector is now sitting on roughly 14.46 billion dollars in unrealized losses. About 40% of Bitcoin treasury companies trade below the net value of their holdings.
The flywheel was elegant in a bull market. Raise capital, buy Bitcoin, Bitcoin goes up, your stock goes up, raise more capital, repeat. MicroStrategy, now called Strategy, pioneered this with debt and volatility instruments. But when prices decline, the flywheel reverses. And that's exactly what's happening.
Strategy itself looks relatively resilient on paper. They hold about 766,970 BTC, roughly 54.5 billion dollars worth, against about 8.2 billion in debt. That's a leverage ratio of around 10 to 13%, with 2.25 billion in cash covering over 2 years of interest and dividends. Debt maturities are staggered from 2027 to 2032. Michael Saylor is even proposing semi-monthly dividends on Strategy's STRC preferred stock to stabilize the price and drive liquidity. Strategy has the balance sheet to weather this.
But not everyone does. Further down the food chain, you have companies like Hyperscale Data reporting 644 BTC and total assets of 93.5 million dollars, which is about 144% of their market cap. That's a massive disconnect, and it tells you the market is pricing in serious doubt about these smaller operators. LM Funding America holds 341 BTC valued at about 22.9 million, while their stock trades around 25 cents a share. Capital B in Europe has grown its treasury to 2,925 BTC and is tracking BTC per fully diluted share as the core metric, which is probably the right way to think about it.
The big picture from an analysis of the sector: about 154 public companies hold roughly 1.18 million BTC, around 5.35% of total supply. That concentration creates both opportunity and systemic risk. If multiple treasury companies need to sell into a downturn to service debt or meet margin calls, that selling pressure amplifies the cycle. The model works brilliantly in bull markets. Whether it survives a sustained bear is the question being answered right now.
Here's the thing to sit with this weekend. Bitcoin just outperformed gold by 22 percentage points during an actual shooting war. Not in a backtest, not in a white paper scenario, in real time. The thesis that Bitcoin only works as a risk-on tech bet is getting harder to defend. It's behaving more like a monetary hedge in a world where the old hedges aren't working the way they used to. That doesn't mean the path is smooth. Miners are squeezed, treasury companies are underwater, and the Fed is stuck. But the signal from the market is that Bitcoin's role is evolving, and fast. Have a good weekend.